The World Health Organization (WHO) has approved a second malaria vaccine, offering a more affordable and accessible alternative to the Mosquirix vaccine. The R21/Matrix-M malaria vaccine has been developed by the University of Oxford and the Serum Institute of India (SII), leveraging Novavax’s adjuvant technology. The decision was based on the recommendations of two expert … Continue reading WHO Approves R21 Malaria Vaccine for Use